Francesco P Schena
Overview
Explore the profile of Francesco P Schena including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
1935
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schena F, Chiurlia S, Abbrescia D, Cox S
Clin Kidney J
. 2024 Jan;
17(1):sfad121.
PMID: 38186900
This narrative review sheds light on the use of transcriptomics in the analysis of kidney biopsies and urinary cell samples from patients with immunoglobulin A nephropathy or lupus nephritis. The...
2.
Inker L, Collier W, Greene T, Miao S, Chaudhari J, Appel G, et al.
Nat Med
. 2023 Jun;
29(7):1867-1876.
PMID: 37330614
Glomerular filtration rate (GFR) decline is causally associated with kidney failure and is a candidate surrogate endpoint for clinical trials of chronic kidney disease (CKD) progression. Analyses across a diverse...
3.
Heerspink H, Inker L, Tighiouart H, Collier W, Haaland B, Luo J, et al.
J Am Soc Nephrol
. 2023 Mar;
34(6):955-968.
PMID: 36918388
Significance Statement: Changes in albuminuria and GFR slope are individually used as surrogate end points in clinical trials of CKD progression, and studies have demonstrated that each is associated with...
4.
Collier W, Inker L, Haaland B, Appel G, Badve S, Caravaca-Fontan F, et al.
Clin J Am Soc Nephrol
. 2023 Feb;
18(2):183-192.
PMID: 36754007
Background: The GFR slope has been evaluated as a surrogate end point for kidney failure in meta-analyses on a broad collection of randomized controlled trials (RCTs) in CKD. These analyses...
5.
Ohyama Y, Yamaguchi H, Ogata S, Chiurlia S, Cox S, Kouri N, et al.
iScience
. 2022 Oct;
25(11):105223.
PMID: 36277451
Galactose (Gal)-deficient IgA1 (Gd-IgA1) is involved in IgA nephropathy (IgAN) pathogenesis. To reflect racial differences in clinical characteristics, we assessed disease- and race-specific heterogeneity in the -glycosylation of the IgA1...
6.
Schena F, Tripepi G, Rossini M, Abbrescia D, Manno C
Clin Kidney J
. 2022 May;
15(5):1028.
PMID: 35503549
[This corrects the article DOI: 10.1093/ckj/sfab263.].
7.
Schena F, Tripepi G, Rossini M, Abbrescia D, Manno C
Clin Kidney J
. 2022 May;
15(5):895-902.
PMID: 35498888
Background: Randomized controlled trials (RCTs) have been conducted, stratifying idiopathic immunoglobulin A nephropathy (IgAN) patients based on the laboratory findings [serum creatinine, estimated glomerular filtration rate (eGFR) and daily proteinuria]....
8.
Schena F, Magistroni R, Narducci F, Abbrescia D, Anelli V, Di Noia T
Pediatr Nephrol
. 2022 Mar;
37(11):2533-2545.
PMID: 35266037
In this narrative review, we focus on the application of artificial intelligence in the clinical history of patients with glomerular disease, digital pathology in kidney biopsy, renal ultrasonography imaging, and...
9.
Neuen B, Tighiouart H, Heerspink H, Vonesh E, Chaudhari J, Miao S, et al.
J Am Soc Nephrol
. 2021 Dec;
33(2):291-303.
PMID: 34862238
Background: Acute changes in GFR can occur after initiation of interventions targeting progression of CKD. These acute changes complicate the interpretation of long-term treatment effects. Methods: To assess the magnitude...
10.
Schena G, Carmosino M, Chiurlia S, Onuchic L, Mastropasqua M, Maiorano E, et al.
Physiol Rep
. 2021 Oct;
9(20):e15058.
PMID: 34676684
Autosomal dominant polycystic kidney disease (ADPKD) disrupts renal parenchyma through progressive expansion of fluid-filled cysts. The only approved pharmacotherapy for ADKPD involves the blockade of the vasopressin type 2 receptor...